{"id":471508,"date":"2021-04-06T08:03:24","date_gmt":"2021-04-06T12:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471508"},"modified":"2021-04-06T08:03:24","modified_gmt":"2021-04-06T12:03:24","slug":"charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/","title":{"rendered":"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities<\/b><\/p>\n<p class=\"bwalignc\"><i>Partnership will provide access to Valence\u2019s machine learning platform to accelerate preclinical drug discovery efforts<\/i><\/p>\n<p>WILMINGTON, Mass. &amp; MONTREAL&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCharles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence\u2019s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimization.\n<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20210406005112\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210406005112\/en\/<\/a><\/p>\n<p>\nBuilding on research done by Valence\u2019s founding team at Mila, the world\u2019s largest deep learning research institute, the Valence platform enables the design of small molecule drug candidates in novel regions of chemical space, followed by rapid optimization against project-specific potency, selectivity, safety, and pharmacology criteria. Valence has pioneered the application of few-shot learning in drug design, allowing the company to unlock prediction tasks for which only small amounts of training data are available, overcoming a critical limitation of existing machine learning technologies in drug discovery.\n<\/p>\n<p><b>Partnering to Accelerate Discoveries <\/b><\/p>\n<p>\nBy combining best-in-class machine learning technologies with Charles River\u2019s end-to-end capabilities, the alliance has the potential to significantly accelerate discovery efforts from hit design through lead optimization.\n<\/p>\n<p>\nThrough the collaboration, Charles River clients will have the option to access Valence\u2019s platform to support their drug discovery efforts. When taking advantage of this option, clients can expect increased diversity in chemical matter being investigated, in combination with more rapid optimization against complex, project-specific design criteria, ultimately reducing timelines and improving success rates for drug discovery projects.\n<\/p>\n<p><b>Approved Quotes<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n\u201cThis collaboration reflects Charles River\u2019s ongoing commitment to enhancing our portfolio of innovative technology solutions. We look forward to leveraging Valence\u2019s unique platform to improve outcomes for our clients.\u201d \u2013 Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River\n<\/li>\n<li>\n\u201cThe Valence platform offers a step-change improvement over existing de novo design technologies. We\u2019ve been consistently impressed by Valence Discovery\u2019s ability to generate high quality chemical matter that\u2019s readily synthesizable, in novel regions of chemical space, from datasets not otherwise accessible to machine learning methods.\u201d \u2013 Grant Wishart, PhD, Director of Computer Aided Drug Design, Charles River\n<\/li>\n<li>\n\u201cWe are thrilled to be partnering with Charles River, a global leader trusted by many of the world\u2019s top pharmaceutical and biotech companies. This collaboration is an important step in furthering our mission of empowering every drug discovery scientist with the latest innovations in AI-enabled drug design.\u201d\u2013 Daniel Cohen, CEO of Valence Discovery\n<\/li>\n<\/ul>\n<p><b>About Valence\u2019s AI-Enabled Drug Design Platform<\/b><\/p>\n<p>\nThe Valence platform expands upon academia-leading research done by the company\u2019s founding team at Mila, the world\u2019s largest deep learning research institute. In particular, Valence has pioneered the application of few-shot learning in drug design, allowing the company to unlock prediction tasks for which only small amounts of training data are available, including novel targets and complex ADME criteria, while also ensuring that AI-generated molecules are of high medicinal chemistry quality and readily synthesizable. In addition, Valence uses active learning and iterative optimization strategies to ensure that only the most information-rich compounds are selected for synthesis, enabling the design of compounds meeting the target potency, selectivity, and ADME criteria in fewer iterations, and with far less data, than otherwise possible.<b \/><\/p>\n<p><b>About Valence Discovery<\/b><\/p>\n<p>\nValence is committed to unlocking the true potential of deep learning in drug design by unifying best-in-class deep learning technologies with intuitive infrastructure to make these technologies more broadly accessible to R&amp;D organizations of all sizes. Valence\u2019s AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners. The company is pioneering the application of few-shot learning in drug design and is developing and deploying novel machine learning methods for molecular property prediction, generative chemistry, and multiparameter optimization. Valence (formerly InVivo AI) was founded in 2018, is advised by deep learning pioneer, Dr. Yoshua Bengio, and is proudly headquartered in Montreal at Mila, the world\u2019s largest deep learning research institute, with an office in Cambridge, Mass. To learn more, please visit<span class=\"bwuline\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.valencediscovery.com&amp;esheet=52406549&amp;newsitemid=20210406005112&amp;lan=en-US&amp;anchor=www.valencediscovery.com&amp;index=1&amp;md5=0c24d47186233c0ba766108c974596f7\">www.valencediscovery.com<\/a><\/span>.\n<\/p>\n<p><b>About Charles River<\/b><\/p>\n<p>\nCharles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.criver.com&amp;esheet=52406549&amp;newsitemid=20210406005112&amp;lan=en-US&amp;anchor=www.criver.com&amp;index=2&amp;md5=7b0fb2a4fe1e7aa86a698aedfe1d5887\">www.criver.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210406005112\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210406005112\/en\/<\/a><\/span><\/p>\n<p><b>Charles River Investor Contact:<br \/>\n<\/b><br \/>Todd Spencer<br \/>\n<br \/>Corporate Vice President, Investor Relations<br \/>\n<br \/>+1-781-222-6455<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:todd.spencer@crl.com\">todd.spencer@crl.com<br \/>\n<\/a><\/p>\n<p><b>Charles River Media Contact:<br \/>\n<\/b><br \/>Amy Cianciaruso<br \/>\n<br \/>Corporate Vice President, Public Relations<br \/>\n<br \/>+1-781-222-6168<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:amy.cianciaruso@crl.com\">amy.cianciaruso@crl.com<br \/>\n<\/a><\/p>\n<p><b>Valence Corporate Contact:<br \/>\n<\/b><br \/>Therence Bois<br \/>\n<br \/>Chief Operating Officer, Valence Discovery<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:hello@valencediscovery.com\">hello@valencediscovery.com<br \/>\n<\/a><\/p>\n<p><b>Valence Media Contact:<br \/>\n<\/b><br \/>Jessica Yingling, Ph.D.<br \/>\n<br \/>Little Dog Communications Inc.<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jessica@litldog.com\">jessica@litldog.com<br \/>\n<\/a><br \/>+1-858-344-8091\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America Canada Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Medical Devices General Health Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210406005112\/en\/836653\/3\/charles_river_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210406005112\/en\/869268\/3\/Valence_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities Partnership will provide access to Valence\u2019s machine learning platform to accelerate preclinical drug discovery efforts WILMINGTON, Mass. &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence\u2019s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimization. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210406005112\/en\/ Building on research done by Valence\u2019s founding team at Mila, the world\u2019s largest deep learning research institute, the Valence platform enables the design of small molecule drug candidates in novel regions of chemical space, followed by rapid &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471508","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities Partnership will provide access to Valence\u2019s machine learning platform to accelerate preclinical drug discovery efforts WILMINGTON, Mass. &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence\u2019s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimization. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210406005112\/en\/ Building on research done by Valence\u2019s founding team at Mila, the world\u2019s largest deep learning research institute, the Valence platform enables the design of small molecule drug candidates in novel regions of chemical space, followed by rapid &hellip; Continue reading &quot;Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T12:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities\",\"datePublished\":\"2021-04-06T12:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/\"},\"wordCount\":905,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/\",\"name\":\"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-06T12:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/","og_locale":"en_US","og_type":"article","og_title":"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities - Market Newsdesk","og_description":"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities Partnership will provide access to Valence\u2019s machine learning platform to accelerate preclinical drug discovery efforts WILMINGTON, Mass. &amp; MONTREAL&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence\u2019s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimization. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20210406005112\/en\/ Building on research done by Valence\u2019s founding team at Mila, the world\u2019s largest deep learning research institute, the Valence platform enables the design of small molecule drug candidates in novel regions of chemical space, followed by rapid &hellip; Continue reading \"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-06T12:03:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities","datePublished":"2021-04-06T12:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/"},"wordCount":905,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/","name":"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-06T12:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210406005112r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-and-valence-discovery-announce-strategic-partnership-to-provide-clients-with-ai-enabled-drug-design-capabilities\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471508"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471508\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}